Campbell & CO Investment Adviser LLC Has $1.46 Million Stake in Pfizer Inc. $PFE

Key Points

• Campbell & CO Investment Adviser LLC significantly increased its stake in Pfizer by purchasing 50,176 shares, marking a 661.1% increase, bringing their total holdings to 57,766 shares valued at approximately $1.46 million.
• Pfizer reported stronger-than-expected quarterly earnings with an EPS of $0.78, surpassing analyst estimates, and announced a quarterly dividend of $0.43 per share, yielding 6.8% annually.
• Wall Street analysts have mixed opinions on Pfizer's stock, holding a consensus rating of "Hold" and a price target averaging around $28.12, with ratings ranging from "Strong Buy" to "Sell."

Campbell & CO Investment Adviser LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 661.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,766 shares of the biopharmaceutical company's stock after acquiring an additional 50,176 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Pfizer were worth $1,464,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the first quarter worth approximately $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter worth approximately $28,000. Finally, Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter worth approximately $28,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6%

Shares of Pfizer stock traded up $0.16 during trading on Wednesday, hitting $25.08. The company's stock had a trading volume of 31,814,192 shares, compared to its average volume of 44,824,848. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The stock has a market cap of $142.57 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The stock has a 50-day moving average price of $24.76 and a two-hundred day moving average price of $24.40.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's payout ratio is currently 91.49%.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. The Goldman Sachs Group raised their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.